NCT03971461View on ClinicalTrials.gov

Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 15, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Meningioma
Interventions
DRUG

Lutathera

administered intravenously every 8 weeks for a total of 4 doses

Trial Locations (2)

10016

NYU Langone Health, New York

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03971461 - Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | Biotech Hunter | Biotech Hunter